Pharmsynthez-Zerde is set to be constructed in Kazakhstan's Shymkent. The facility, which will produce drugs for the treatment of cardiovascular diseases, cancer, and HIV/AIDS, is a joint venture (JV) between Kazakhstan and Russian pharmaceutical company Pharmsynthez. The facility is anticipated to manufacture over 3 million packages a year, with the launch of the full production capacity expected in 2017.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.505 RUB | +10.15% |
|
-.--% | -.--% |
2023 | Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 15.5M | |
+55.19% | 815B | |
+45.57% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+19.43% | 247B | |
+3.68% | 229B | |
+14.08% | 219B | |
+10.86% | 171B | |
-2.78% | 159B |
- Stock Market
- Equities
- LIFE Stock
- News Pharmsynthez
- Pharmsynthez to Open Joint Production Facility in Kazakhstan in 2017